You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The three tests run on the firm's Vidas systems and expand the firm's footprint in vector-borne disease.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
The test is aimed at detecting Zika antibodies in a highly specific way that avoids cross-reactivity with the dengue virus, according to the firm.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
The method detects dengue virus from blood serum or plasma using DNA nanostructures and aptamers and can potentially be read with a portable fluoroscope.
Eurobio Scientific will also develop new test kits for the T-COR 8, a real-time PCR thermocycler originally developed for the US Army.
The point-of-care diagnostics firm tallied $9.6 million in revenues in the second quarter, besting analysts' consensus estimate of $8.8 million.
The firm said that its multiplex point-of-care test uses 10 microliters of blood from a fingertip and provides quantitative results in about 15 minutes.
The firm is working with a new center in Dakar, Senegal, that will deploy new tests based on the platform to support early detection of tropical diseases.
The firm said it has multiple point-of-care tests available in Brazil and anticipates soon fulfilling an order for its dengue, chikungunya, and Zika tests.